David G. Maloney
Fred Hutchinson Cancer Center
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
CAR-T cell therapy research
Strong evidence · 9 supporting papers · latest 2026
Lymphoma Diagnosis and Treatment
Strong evidence · 7 supporting papers · latest 2026
Integrated Circuits and Semiconductor Failure Analysis
Strong evidence · 1 supporting paper · latest 2025
Chronic Lymphocytic Leukemia Research
Solid evidence · 1 supporting paper · latest 2026
Monoclonal and Polyclonal Antibodies Research
Solid evidence · 3 supporting papers · latest 2026
Cutaneous lymphoproliferative disorders research
Solid evidence · 3 supporting papers · latest 2026
Virus-based gene therapy research
Solid evidence · 2 supporting papers · latest 2026
HER2/EGFR in Cancer Research
Solid evidence · 2 supporting papers · latest 2025
Publications (11)
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
2025DOIPMID 41100801
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies
2025DOIPMID 41207382
A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma
2026DOIPMID 42389828
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma
2026DOIPMID 42600120
Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)–targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH).
2026DOI
535 EVEREST-2: a phase 1/2 study of A2B694, a logic-gated Tmod CAR T therapy to treat solid tumors expressing mesothelin (MSLN) with HLA-A*02 loss of heterozygosity: initial safety and efficacy results
2025DOI
585 DENALI-1: a seamless phase 1/2 study of A2B395, a logic-gated, allogeneic, Tmod CAR T therapy, in patients with EGFR-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
2025DOI
Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis
2025DOI
Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study
2026DOIPMID 42237652
BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials
2026DOIPMID 41918932
Autologous and allogeneic hematopoietic cell transplantation in children and adults with high-risk anaplastic large cell lymphoma
2026DOIPMID 42100396
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Fred Hutchinson Cancer Center
Source: OpenAlex · retrieved 2026-09-29
Source: ScienceWe Extractor · retrieved 2026-09-27